[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"OvationLab\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":107},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,67,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100640688","clinical-trial-evaluating-the-impact-of-a-dietary-supplement-containing-humic-and-fulvic-acid-on-epigenetic-markers-of-biological-age-detoxification-inflammation-and-oxidative-stress-100640688",false,"NCT07579845","Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress","Inclusion Criteria:\n\n1. Adult females or males age ≥ 40 years\n2. Ability to read and speak English\n\nExclusion Criteria:\n\n1. Current use of a dietary supplement containing fulvic or humic acid\n2. Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella\n3. Known allergies to any ingredients in the product\n4. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks\n5. Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol\n6. Participants unable to provide consent",true,"ALL","40 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.",[26,27,28],"Detoxification","Inflammation","Biological Aging","RECRUITING","2026-05-27",{"date":32,"type":33},"2026-05-29","ACTUAL",{"date":35,"type":33},"2026-05-05",{"date":37,"type":20},"2026-09",{"name":39,"class":40},"OvationLab","NETWORK",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100640109","associations-between-household-mold-levels-and-physical-and-mental-health-a-mold-and-mycotoxin-testing-research-registry-100640109","NCT07605078","Associations Between Household Mold Levels and Physical and Mental Health: A Mold and Mycotoxin Testing Research Registry","Inclusion Criteria:\n\n* All Dust Test users who provide informed consent for deidentified analysis and peer-reviewed publication of their data will be eligible to participate in the research registry.\n\nExclusion Criteria:\n\n* Dust Test users who do not provide informed consent for deidentified analysis and peer-reviewed publication of their data.",{"count":49,"type":20},2500,"5 Years","OBSERVATIONAL","The primary purpose of this study is to evaluate cross-sectional associations between mold exposures identified with The Dust Test and self-reported physical health, emotional health, and medical diagnoses. In addition, associations between mold exposures and mycotoxin levels among users who have done mycotoxin lab testing will also be evaluated.",[54,55],"Mold Illness","Mold or Dust Allergy",[57],"Mold","NOT_YET_RECRUITING","2026-05-18",{"date":61,"type":33},"2026-05-22",{"date":63,"type":20},"2026-04-27",{"date":65,"type":20},"2029-04",{"name":39,"class":40},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":86,"locationsCount":41},"100620285","terraflora-daily-care-and-gastrointestinal-health-100620285","NCT07355634","Terraflora Daily Care and Gastrointestinal Health","A Randomized, Placebo-Controlled Trial Evaluating the Impact of a Synbiotic Dietary Supplement on Markers of Gastrointestinal Health","Inclusion Criteria:\n\n1. Adult males or females age ≥ 25 years\n2. Ability to read and speak English\n3. Dysbiosis (≥3 on GA-Map Dysbiosis Score) on a stool test (GI360 Profile, Doctor's Data, St. Charles, Illinois)\n\nExclusion Criteria:\n\n1. Daily use within the past month of any probiotic or prebiotic supplement\n2. Current diagnosis of inflammatory bowel disease, including Crohn's or ulcerative colitis\n3. Current daily usage of non-steroidal anti-inflammatory drugs (NSAID), proton pump inhibitors (PPI), or antibiotic medications\n4. Current daily tobacco smoker\n5. Known allergies to any substance in the study products\n6. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks\n7. Current diagnosis of any other chronic health condition (e.g., cancer, chronic kidney disease) deemed clinically contraindicated for the study protocol\n8. Current participation in another clinical trial\n9. Participants unable to provide consent","25 Years",{"count":76,"type":20},40,[23],"A 12-week, randomized, double-blind, placebo-controlled clinical trial will be conducted evaluating the effectiveness of Enviromedica - Terraflora Daily Care on markers of gastrointestinal function and symptoms.",[80],"Gastrointestinal",{"date":82,"type":33},"2026-05-11",{"date":84,"type":33},"2026-01-12",{"date":37,"type":20},{"name":39,"class":40},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":15,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":41},"100624331","effects-of-biocidin-on-oral-biofilms-100624331","NCT07408245","Effects of Biocidin on Oral Biofilms","Prospective Human Study Evaluating the Effects of Biocidin Liquid on Oral Biofilms: An Open-label Pilot Study","Inclusion Criteria:\n\n1. Adult females or males age ≥ 25 years\n2. Ability to read and speak English\n3. Willingness to take use oral Biocidin as directed for two weeks\n4. Willingness not to change any other oral health practices for two weeks\n5. Willingness not to change dietary habits for two weeks\n6. Willingness to perform a SimplyPERIO oral microbiome test before and after the two-week Biocidin intervention\n\nExclusion Criteria:\n\n1. Current use of oral Biocidin or botanical mouthwash\n2. Use of antibiotics within the past 30 days\n3. Current use of fixed intraoral orthodontic appliances (e.g., dental braces, fixed retainers, or similar devices)\n4. Known allergies to any of the ingredients in the product\n5. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks\n6. Participants unable to provide consent",{"count":19,"type":20},[23],"The primary purpose of this study is to evaluate the effects of Biocidin liquid on oral biofilms among healthy adults. A single-arm, open-label prospective study will be conducted evaluating the impact of two weeks of supplementation with label dosing of Biocidin liquid on oral biofilms as assessed by SimplyPERIO (Spectrum Solutions, Salt Lake City, UT).",[98],"Biofilm","2026-03-09",{"date":101,"type":33},"2026-03-11",{"date":103,"type":33},"2026-02-17",{"date":105,"type":20},"2026-04",{"name":39,"class":40},""]